Search results
2 dni temu · We conducted a phase 3, international, open-label, randomized, controlled trial. Men with stage T1 or T2 prostate cancer, a Gleason score of 3+4 or less, and a prostate-specific antigen (PSA ...
12 lut 2021 · Stereotactic body radiotherapy, i.e., high-precision radiotherapy delivering high doses within a few treatment sessions, is a very convenient treatment option, which has been shown to be effective and well tolerated in prostate cancer patients with low- or intermediate-risk profiles.
5 cze 2020 · When utilizing modern techniques that allow the precise sculpting of a dose distribution that delivers high doses to the prostate and lower doses to surrounding normal tissues over five or fewer treatments, this treatment is called stereotactic body radiotherapy (SBRT).
5. Can I get SBRT for High-Risk Prostate Cancer? Yes, as of 2020, SBRT is considered a standard of care option for patients with high-risk and very-high risk prostate cancer. Dr. Kishan led the largest study of SBRT for high-risk prostate cancer, which was published in early 2021 and pooled data from seven trials from across the world (https ...
21 lut 2023 · Background: SBRT in high risk (HR), node positive (N+) and oligometastatic (OM) prostate cancers is limited by pelvic nodal coverage, larger treatment volumes and use of hormone therapy. We report the safety, efficacy and patient reported quality of life measures (QOL) for SIB-SBRT for prostate and pelvic nodal treatment in HR, N+ and OM (non ...
7 lip 2022 · The PRIME trial (NCT03561961) is a phase III RCT comparing the efficacy of moderate hypofractionation (50 Gy to pelvis and 66–68 Gy to prostate in 25 fractions) with SBRT (25 Gy to pelvis, 35–36.5 Gy to prostate, and 30–35 Gy to gross nodes all in 5 fractions) in HRPC and N+ prostate cancer.
19 cze 2024 · Our systematic review aims to summarize evidence with stereotactic body radiotherapy (SBRT) in castration-resistant prostate cancer (CRPC).
